Study of APG-2575 as a Single Agent or in Combination With Other Therapeutic Agents for CLL/SLL (NCT04215809)
APG-2575CU101, A Phase Ib Study of APG-2575 as a Single Agent or in Combination With Other Therapeutic Agents in Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
🩺 Plain-English Summary (8th-Grade Level)
Assess the safety and tolerability, identify dose-limiting toxicities (DLT) and determine the maximum tolerated dose (MTD) / recommended phase 2 dose (RP2D) of lisaftoclax.
Who can join: Review the eligibility criteria below.
Location: City of Hope — Duarte, California
Age range: 18 Years to 85 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (9 Sites)
- City of Hope — Duarte, California
- Mayo Clinic — Jacksonville, Florida
- Dana Farber Cancer Institute — Boston, Massachusetts
- Novant Health — Charlotte, North Carolina
- Gabrail Cancer Center — Canton, Ohio
- Cleveland Clinic — Cleveland, Ohio
- Swedish Health — Seattle, Washington
- Princess Alexandria Hospital — Brisbane, Queensland
- Frankston Private Hospital — Melbourne, Victoria
📞 Contact the Study Coordinator
Phone: (301) 520-5964
Email: Laura.Glass@ascentage.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in CLL/SLL
- Autologous CD19 CAR-T Cell Therapy (SYNCAR-001) + Orthogonal IL-2 (STK-009) in Subjects With CD19+ Hematologic Malignancies — Duarte, California
- Study of Epcoritamab as a Consolidation Therapy in CLL/SLL — Cincinnati, Ohio
- Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies. — Durham, North Carolina
- Global Trial in APG2575 for Patients With CLL/SLL — Tuscon, Arizona
Explore by condition: All CLL/SLL clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.